OSP6101

OSP6101 is a preclinical-stage drug candidate being developed through a partnership between Oncocross and ST Pharm for the treatment of infectious diseases. The compound was identified using Oncocross's proprietary RAPTOR AI™ platform, an AI-driven drug discovery engine that utilizes transcriptomic data to identify optimal therapeutic indications for drug candidates. As of the current pipeline status, OSP6101 is in the in vitro preclinical stage of development. The specific biological target and molecular mechanism of action have not been publicly disclosed, but the project leverages the 'OSP' collaborative framework established between Oncocross and ST Pharm to accelerate the development of novel therapies.